Celularity Celularity
  • Home
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Manufacturing
    • Biobanking
    • Tour Our Facility
    • Expanded Access Policy
  • Science
    • Power of Placenta
    • NK Cell Platform
    • T Cell Platform
    • Exosomes
    • Advanced Biomaterials
  • Pipeline
  • Newsroom
  • Investors
    • Investor Relations
    • SEC Filings
    • Corporate Governance
  • Careers
Celularity
MENU

COVID-19

Updates

See latest Press Relases
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

14 Apr 2025 7 Minutes 0 1128
...
Avatar photo
Celularity Inc.
Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology

Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology

7 Apr 2025 6 Minutes 0 1132
...
Avatar photo
Celularity Inc.
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

25 Feb 2025 7 Minutes 0 1131
...
Avatar photo
Celularity Inc.
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

24 Feb 2025 8 Minutes 0 1127
...
Avatar photo
Celularity Inc.
MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs

MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs

27 Jan 2025 5 Minutes 0 1120
...
Avatar photo
Celularity Inc.
Load more
Celularity_Nasdaq_CELU-1

Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases.

Company

  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers

Science

  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing

Investors

  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2025. All rights reserved.     Privacy Policy     Terms & Conditions

Company
  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers
Science
  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing
Investors
  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2024. All rights reserved.
Privacy Policy     Terms & Conditions